Onychomysosis
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Uzipho lozwane luchatshazelwe yi Onychomysosis
Unyawo lomntu olunosulelo lwezinzipho zokungunda kwiiveki ezilishumi kwikhosi yonyango lomlomo lwe-terbinafine. Qaphela band ukukhula iinzipho esempilweni emva iinzipho eseleyo abosulelekileyo.
References
I-antifungals ye-systemic yolona nyango lusebenzayo. Uhlalutyo lwe-Meta lubonisa amazinga onyango lwe-mycotic ngolu hlobo lulandelayo: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48% . Ukonakaliswa kwezikhonkwane okuhambisanayo nako kwandisa amazinga okunyanga. Unyango lwangaphakathi olune ciclopirox alusebenzi kangako; inezinga lokungaphumeleli elingaphezu kwe-60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
I-Onychomycosis yintsholongwane yefungal echaphazela iinzipho. Xa ibangelwa yidermatophytes, ibizwa ngokuba tinea unguium. I-Onychomycosis ibandakanya izifo ezibangelwa yi-dermatophytes, igwele kunye nokungunda. Ingxaki yezikhonkwane engabangelwa lusulelo lomngundo ibizwa ngokuba yi nail dystrophy. Nangona inokuchaphazela zombini iminwe kunye neminwe, i-toenail onychomycosis ixhaphake kakhulu. Eli nqaku lixubusha iinkalo ezahlukeneyo ze-toenail onychomycosis, njengempembelelo yayo, iintlobo zeklinikhi, izigaba, ukuxilongwa, kunye nonyango. Nangona ingasongela ubomi, i-onychomycosis inokukhokelela kwiingxaki ezinzulu ezifana ne-cellulitis, i-sepsis, ukusuleleka kwamathambo, umonakalo wezicubu kunye nokulahleka kwezipikili.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Terbinafine liyeza elilwa nosulelo lomngundo ngokuvala i-squalene epoxidase. Isebenza ngokuchasene neendidi ezininzi zomngundo wolusu kwaye yamkelwe ukunyanga ukungunda kweenzipho xa ithathwa ngomlomo. Ngelixa uninzi lweziphumo ebezingalindelekanga ezinjengeentloko kunye nemiba yesisu zincinci kwaye zihamba zodwa, utshintsho kwincasa (dysgeusia) inokwahluka ukusuka komncinci ukuya kobunzima, ngamanye amaxesha kukhokelela ekulahlekeni kobunzima. Utshintsho lwencasa olusisigxina lunqabile kodwa luxeliwe.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
I-Onychomycosis yintsholongwane yefungal echaphazela izikhonkwane. Malunga ne-90% yosulelo lwezikhonkwane kunye ne-75% yosulelo lweminwe lubangelwa ngumngundo (Trichophyton mentagrophytes, Trichophyton rubrum) . Iimpawu ziquka ukuguquka kwemibala yeenzipho, ukujiya, ukuhlukana nebhedi yeenzipho, kunye nokukhula. Unyango lubandakanya amayeza aselwayo afana ne-terbinafine okanye i-itraconazole, kunye nonyango lwangaphakathi lube lukhetho kwiimeko ezithambileyo ukuya kweziphakathi.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Iyeza le-antifungal terbinafine elithathwe ngomlomo libonakala lilelona lisebenzayo kodwa i-terbinafine inyanyaniswa nesiphumo secala lesibindi.
Onychomysosis yenzeka malunga ne-10 lepesenti yabantu abadala, nabantu abadala abachaphazeleka rhoqo. Amadoda achaphazeleka rhoqo kunamabhinqa. Onychomysosis imele malunga nesiqingatha sesifo sezikhonkwane. Oku kuthetha ukuba ukukhubazeka kweenzwane kunokuvela kwezinye izizathu ngaphandle kwe-onychomycosis.
○ Unyango ― OTC Amachiza
Kunzima ukunyanga i-onychomycosis ngamayeza e-topical kuba kunzima ukuba izidakamizwa zingene kwi-toenails eqiniweyo.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Unyango
Unyango lwexesha elide ludla ngokufuneka de uzipholo olusulelekileyo lususwe ngokupheleleyo.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer